1 May 2024
Advanced
Medical Solutions Group plc
("AMS" or
the "Group")
Total Voting
Rights
In accordance with
Disclosure and Transparency Rule 5.6.1, the issued share capital of
Advanced Medical Solutions Group plc as at 1 May 2024
comprises 217,412,434
ordinary shares of 5p each with
voting rights. There are no shares held in
treasury.
The above figure may
be used by shareholders as the denominator for the calculations by
which they will determine if they are required to notify their
interest in, or a change to their interest in, the Company under
the FCA's Disclosure and Transparency Rules.
- Ends
-
For
further information, please visit www.admedsol.com
or
contact:
|
Advanced Medical Solutions Group plc
|
Tel: +44
(0) 1606 545508
|
|
Chris Meredith, Chief Executive
Officer
Eddie Johnson, Chief Financial
Officer
Michael King, Investor
Relations
|
|
|
|
|
|
ICR
Consilium
|
Tel: +44
(0) 20 3709 5700
|
|
Mary-Jane Elliott / Lucy
Featherstone
|
AMS@consilium-comms.com
|
|
|
|
|
Investec Bank plc (NOMAD and
Broker)
|
Tel: +44
(0) 20 7597 5970
|
|
Gary Clarence / David
Anderson
HSBC Bank plc (Broker)
Sam McLennan / Joe Weaving /
Stephanie Cornish
|
Tel: 44
(0) 20 7991 8888
|
About Advanced Medical Solutions Group plc
AMS is a world-leading independent
developer and manufacturer of innovative tissue-healing technology,
focused on quality outcomes for patients and value for payers. AMS
has a wide range of surgical products including tissue adhesives,
sutures, haemostats, internal fixation devices and internal
sealants, which it markets under its brands LiquiBand®,
RESORBA®, LiquiBandFix8® and
Seal-G®. AMS also supplies wound care dressings such as
silver alginates, alginates and foams through its
ActivHeal® brand as well as under white label.
Since 2019, the Group has made five acquisitions: Sealantis, an
Israeli medical device company with a patent-protected sealant
technology platform; Biomatlante, an established French developer
and manufacturer of innovative surgical biomaterial technologies,
Raleigh, a UK leading coater and converter of materials
predominately for woundcare and bio-diagnostics products, AFS
Medical, an Austrian a specialist surgical
business with a focus on minimally invasive procedures, and
Connexicon Medical, an Irish tissue
adhesives specialist.
AMS's products, manufactured in the
UK, Germany, France, the Netherlands, the Czech Republic and
Israel, are sold globally via a network of multinational or
regional partners and distributors, as well as via AMS's own direct
sales forces in the UK, Germany, Austria, the Czech Republic and
Russia. The Group has R&D innovation hubs in the UK, Germany,
France, Ireland and Israel. Established in 1991, the Group has more
than 900 employees. For more information, please
see www.admedsol.com.